280 related articles for article (PubMed ID: 25711510)
1. Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis.
Propst AJ; Jarvis GE; Margolese HC
Clin Schizophr Relat Psychoses; 2016; 9(4):173-6. PubMed ID: 25711510
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole-Associated Hypoprolactinemia in the Clinical Setting.
Sogawa R; Shimomura Y; Minami C; Maruo J; Kunitake Y; Mizoguchi Y; Kawashima T; Monji A; Hara H
J Clin Psychopharmacol; 2016 Aug; 36(4):385-7. PubMed ID: 27281387
[TBL] [Abstract][Full Text] [Related]
3. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
Tasaki M; Yasui-Furukori N; Yokoyama S; Shinozaki M; Sugawara N; Shimoda K
Neuropsychopharmacol Rep; 2021 Sep; 41(3):379-384. PubMed ID: 34189861
[TBL] [Abstract][Full Text] [Related]
4. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
Crespo-Facorro B; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Valdizan EM; Pérez-Iglesias R; Amado-Señaris JA; Teresa Garcia-Unzueta M; Labad J; Correll C; Ayesa-Arriola R
Schizophr Res; 2017 Nov; 189():134-141. PubMed ID: 28223031
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole possibly worsens psychosis.
Ramaswamy S; Vijay D; William M; Sattar SP; Praveen F; Petty F
Int Clin Psychopharmacol; 2004 Jan; 19(1):45-8. PubMed ID: 15101571
[TBL] [Abstract][Full Text] [Related]
6. [Aripiprazole: a new atypical antipsychotic drug].
Fischer B; Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
Adan-Manes J; Garcia-Parajua P
J Clin Pharm Ther; 2009 Apr; 34(2):245-6. PubMed ID: 19250146
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.
Yang HJ; Kim SG; Seo EH; Yoon HJ
BMC Psychiatry; 2022 Jan; 22(1):74. PubMed ID: 35093063
[TBL] [Abstract][Full Text] [Related]
9. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole in the treatment of Alzheimer's disease.
De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
Malla A; Mustafa S; Rho A; Abadi S; Lepage M; Joober R
Schizophr Res; 2016 Jul; 174(1-3):120-125. PubMed ID: 27157800
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
13. [Aripiprazole, gambling disorder and compulsive sexuality].
Mété D; Dafreville C; Paitel V; Wind P
Encephale; 2016 Jun; 42(3):281-3. PubMed ID: 26923999
[TBL] [Abstract][Full Text] [Related]
14. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
15. Severe exacerbation of psychosis after sudden withdrawal of chlorpromazine in the treatment of methamphetamine-associated psychosis with aripiprazole and chlorpromazine: 2 case reports.
Wang G; Devi Thakoor JP; Wang X; Hao W
J Addict Med; 2014; 8(6):479-81. PubMed ID: 25303986
[TBL] [Abstract][Full Text] [Related]
16. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
17. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
18. Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.
Selfani K; Soland VL; Chouinard S; Huot P
Neurologist; 2017 Jan; 22(1):24-28. PubMed ID: 28009769
[TBL] [Abstract][Full Text] [Related]
19. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
Jen YW; Hwang TJ; Chan HY; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Lin YT; Chien YL; Chen WJ
BMC Psychiatry; 2020 Nov; 20(1):552. PubMed ID: 33228575
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
Hoffer ZS; Roth RL; Mathews M
Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
